Pharmamarketeer
wet- en regelgeving

Johnson’s COVID-19 vaccine under scrutiny at EMA after 4 ‘serious cases’ of unusual blood clots

12 april 2021
FiercePharma

COVID-19

AstraZeneca’s COVID-19 vaccine has dominated headlines as reports of rare blood clots mounted, but now European drug safety regulators are investigating potential clotting risks from Johnson & Johnson’s vaccine.

So far in the J&J vaccine’s U.S. rollout, EU officials have tracked three cases of unusual blood clots with low blood platelets following vaccination, the European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee said Friday. Another case came in a clinical trial. One of the cases was fatal.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)